Kang Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kang Wu has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Bingjiao Zhao
Department of Orthodontics, Shanghai Stomatological Hospital & School of Stomatology, Fudan University, Shanghai, China
1 shared publication Chuangchuang Mu
Department of Macromolecular Science, Department of Orthodontics, Multidisciplinary Consultant Center, Shanghai Stomatological Hospital & School of Stomatology, Fudan University, Shanghai, 200433, China
1 shared publication- Dan Zhang
School of Ophthalmology & Optometry, Eye Hospital, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou, Zhejiang 325027, China
1 shared publication Fengcheng Chu
Orthopedic Institute, Department of Orthopedics, The First Affiliated Hospital, Soochow University, Suzhou, China
1 shared publication- Hua Yang
Hebei university of Technology
1 shared publication - Huajian Gao
Mechano-X Institute, Applied Mechanics Laboratory, Department of Engineering Mechanics, Tsinghua University, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 1 July 2025
- Published by KEAI Publishing in Bioactive Materials
- Vol. 49, 255-270
A sequential drug delivery system based on silk fibroin scaffold for effective cartilage repair
Endogenous repair of cartilage defects is a preferential strategy for cartilage repair, but always hindered by insufficient early-stage cells and incomplete cell differentiation at later stages. For in-situ cartilage regeneration, it is crucial to develop a sequential drug release system capable of recruiting endogenous bone marrow mesenchymal stem cells (BMSCs) and promoting their chondrogenic differentiation. Herein, based on our long-term and fruitful research on silk fibroin (SF) porous scaffolds, a cell-free sequential drug delivery SF scaffold was developed. BMSCs affinity peptide PFSSTKT (PFS) was coated on the surface of SF scaffold, in which chondrogenic inducer kartogenin (KGN) and anti-inflammatory factor dexamethasone (DEX) were loaded. PFS was rapidly released within the first 10 days while KGN and DEX could be released over 28 days. The scaffold promoted BMSCs migration and chondrogenic differentiation through the release of PFS and KGN in vitro. Finally, the sequential drug released by the implanted SF scaffolds in rats indeed recruited endogenous BMSCs and significantly promoted the in-situ regeneration of their knee cartilage defects. In summary, this study not only introduces a green and environmentally friendly all silk-based sequential drug delivery system, but also provides an effective tissue engineering functional scaffold for in-situ cartilage regeneration.
- 1 July 2025
- Published by KEAI Publishing in Bioactive Materials
- Vol. 49, 255-270
Open AccessA sequential drug delivery system based on silk fibroin scaffold for effective cartilage repair
Endogenous repair of cartilage defects is a preferential strategy for cartilage repair, but always hindered by insufficient early-stage cells and incomplete cell differentiation at later stages. For in-situ cartilage regeneration, it is crucial to develop a sequential drug release system capable of recruiting endogenous bone marrow mesenchymal stem cells (BMSCs) and promoting their chondrogenic differentiation. Herein, based on our long-term and fruitful research on silk fibroin (SF) porous scaffolds, a cell-free sequential drug delivery SF scaffold was developed. BMSCs affinity peptide PFSSTKT (PFS) was coated on the surface of SF scaffold, in which chondrogenic inducer kartogenin (KGN) and anti-inflammatory factor dexamethasone (DEX) were loaded. PFS was rapidly released within the first 10 days while KGN and DEX could be released over 28 days. The scaffold promoted BMSCs migration and chondrogenic differentiation through the release of PFS and KGN in vitro. Finally, the sequential drug released by the implanted SF scaffolds in rats indeed recruited endogenous BMSCs and significantly promoted the in-situ regeneration of their knee cartilage defects. In summary, this study not only introduces a green and environmentally friendly all silk-based sequential drug delivery system, but also provides an effective tissue engineering functional scaffold for in-situ cartilage regeneration.
- Open Access
- 16 May 2024
- Published by Elsevier in Mechanobiology in Medicine
- Vol. 2 (3) , 100079
Mechanobiomaterials: Harnessing mechanobiology principles for tissue repair and regeneration
- 16 May 2024
- Published by Elsevier in Mechanobiology in Medicine
- Vol. 2 (3) , 100079
Open AccessMechanobiomaterials: Harnessing mechanobiology principles for tissue repair and regeneration
- Open Access
- 18 November 2022
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 10, 1057904
A TGF-loading hydrogel scaffold capable of promoting chondrogenic differentiation for repairing rabbit nasal septum cartilage defect
Hydrogel-based tissue engineering has been widely used to repair cartilage injury. However, whether this approach can be applied to treat nasal septum cartilage defects remains unclear. In this study, three gelatin methacrylate-based scaffolds loaded with transforming growth factor (TGF)-β1 (GelMA-T) were prepared, and their effects on repair of nasal septum cartilage defects were examined. In vitro, the GelMA-T scaffolds showed good biocompatibility and promoted the chondrogenic differentiation of bone mesenchymal stem cells. Among three scaffolds, the 10% GelMA-T scaffold promoted chondrogenic differentiation most effectively, which significantly improved the expression of chondrocyte-related genes, including Col II, Sox9, and ACAN. In vivo, 10% GelMA-T scaffolds and 10% GelMA-T scaffolds loaded with bone mesenchymal stem cells (BMSCs; 10% GelMA-T/BMSCs) were transplanted into a nasal septum cartilage defect site in a rabbit model. At 4, 12, and 24 weeks after surgery, the nasal septum cartilage defects exhibited more complete repair in rabbits treated with the 10% GelMA-T/BMSC scaffold as demonstrated by hematoxylin & eosin, safranine-O, and toluidine blue staining. We showed that GelMA-T/BMSCs can be applied in physiological and structural repair of defects in nasal septum cartilage, providing a potential strategy for repairing cartilage defects in the clinic.
- 18 November 2022
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 10, 1057904
Open AccessA TGF-loading hydrogel scaffold capable of promoting chondrogenic differentiation for repairing rabbit nasal septum cartilage defect
Hydrogel-based tissue engineering has been widely used to repair cartilage injury. However, whether this approach can be applied to treat nasal septum cartilage defects remains unclear. In this study, three gelatin methacrylate-based scaffolds loaded with transforming growth factor (TGF)-β1 (GelMA-T) were prepared, and their effects on repair of nasal septum cartilage defects were examined. In vitro, the GelMA-T scaffolds showed good biocompatibility and promoted the chondrogenic differentiation of bone mesenchymal stem cells. Among three scaffolds, the 10% GelMA-T scaffold promoted chondrogenic differentiation most effectively, which significantly improved the expression of chondrocyte-related genes, including Col II, Sox9, and ACAN. In vivo, 10% GelMA-T scaffolds and 10% GelMA-T scaffolds loaded with bone mesenchymal stem cells (BMSCs; 10% GelMA-T/BMSCs) were transplanted into a nasal septum cartilage defect site in a rabbit model. At 4, 12, and 24 weeks after surgery, the nasal septum cartilage defects exhibited more complete repair in rabbits treated with the 10% GelMA-T/BMSC scaffold as demonstrated by hematoxylin & eosin, safranine-O, and toluidine blue staining. We showed that GelMA-T/BMSCs can be applied in physiological and structural repair of defects in nasal septum cartilage, providing a potential strategy for repairing cartilage defects in the clinic.